RxDoctor Payments Data

Javier Hernandez

Family · Bakersfield, CANPI 1083969695

Payments from drug & device makers

$1,205in general payments, 2019–2025

Across 57 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dynavax Technologies Corporation$176
  • GSK$167
  • AbbVie$110
  • Merck$68
  • Lilly USA, LLC$66
  • Novo Nordisk$66
  • plus $553 from 15 others

What the payments were for

  • Food & beverage$1,205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,205 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$1,700
Medicare patients
71
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$158,737
TrulicityDulaglutide60$86,236
OzempicSemaglutide63$54,773
TradjentaLinagliptin47$54,129
JanuviaSitagliptin Phosphate39$52,570
RybelsusSemaglutide35$39,858
FarxigaDapagliflozin Propanediol34$36,016
EliquisApixaban14$11,478
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,481
DapagliflozinDapagliflozin Propanediol12$6,075
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$4,971
Atorvastatin Calcium450$3,397
Ezetimibe24$2,417
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm11$2,154
Metformin Hcl279$1,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$66$94,63198 claims
Lilly USA, LLCTrulicity$66$86,23660 claims
MerckJanuvia$68$52,57039 claims
AstraZenecaFarxiga$26$36,01634 claims
PfizerEliquis$44$11,47814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →